160730-51-8

Basic information

• Product Name: 2-{[(8beta,10xi)-6-methylergolin-8-yl]methyl}-1H-isoindole-1,3(2H)-dione
• CAS NO: 160730-51-8
• Molecular Formula: C₂₄H₂₃N₃O₂
• Molecular Weight: 385.4583
• Mol File: 160730-51-8.mol

Chemical Properties

• Boiling Point: 595.5°C at 760 mmHg
• Flash Point: 314°C
• Density: 1.328g/cm³
• Vapor Pressure: 3.79E-14mmHg at 25°C
• Refractive Index: 1.692
• CAS DataBase Reference: 2-{[(8beta,10xi)-6-methylergolin-8-yl]methyl}-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{[(8beta,10xi)-6-methylergolin-8-yl]methyl}-1H-isoindole-1,3(2H)-dione(160730-51-8)
• EPA Substance Registry System: 2-{[(8beta,10xi)-6-methylergolin-8-yl]methyl}-1H-isoindole-1,3(2H)-dione(160730-51-8)

Safety Data

• Hazardous Substances Data: 160730-51-8(Hazardous Substances Data)

Upstream product

• 136918-14-4 phthalimide 
• 58752-31-1 6-methyl-8β-tosyloxymethyl-ergoline 
• 18051-16-6 9,10-dihydrolysergol 
• 3006-19-7 9,10-dihydrolysergic acid methyl ester 
• 5878-43-3 9,10-dihydrolysergic acid 

Downstream Products

• 95688-34-9 FCE 22716 

Relevant articles and documents

Serotonergic ergoline derivatives

Novel classes of 13- and 14-tertbutyl-ergoline derivatives were prepared, and characterised in vitro for their affinity for adrenergic, dopaminergic and serotonergic binding sites. This study particularly examines the importance of the presence and the position of the tert-butyl group in conferring either significant 5-HT(1A) or 5-HT2 affinity and selectivity respectively.

Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity

A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were tested in conscious spontaneously hypertensive rats and in rats with unilateral 6- hydroxydopamine-induced lesions of the substantia nigra. (5R,8R,10R)-6- Alkyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18- fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4- Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active than bromocriptine mesylate and pergolide mesylate, respectively. Several compounds exhibited potent antihypertensive activity. Structure- activity relationships for antihypertensive and dopaminergic activities are discussed.